Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Roman Tiraspolsky / Shutterstock.com Party City (NYSE: PRTY ) stock is in the news Monday as investors prepare for the retail company to file for bankruptcy. While there’s no official filing just ye...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: shutterstock.com/Romix Image Why is Voyager Therapeutics (NASDAQ: VYGR ) stock today up while Neurocrine Biosciences (NASDAQ: NBIX ) is down? Evidently, today’s movement is because of a deal between t...
Voyager Therapeutics ( NASDAQ: VYGR ) added ~29% pre-market Monday after the clinical-stage biotech announced a licensing agreement with Neurocrine Biosciences ( NASDAQ: NBIX ) for multiple gene therapies targeted at neurological diseases. The partnership leverages Voyager...
- Voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial milestones, tiered royalties on net sales, program funding, and an option to elect 50/50 cost- and profit-...
Summary Two new Breakout Stocks for Week 2 with better than 10% short-term upside potential and one Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. Momentum Gauge trading signal turned positive this week and new portfolios are all positive with strong gains to st...
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the upcoming 41st Annual J.P....
CAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Grace E. Colón, Ph.D., to its Board of Directors. Dr. Colón has...
Voyager Therapeutics, Inc. (VYGR) Q3 2022 Results Conference Call November 08, 2022 08:30 AM ET Company Participants Alfred Sandrock - Chief Executive Officer Peter Pfreundschuh - Chief Financial Officer Todd Carter - Chief Scientific Officer Conference Cal...
Voyager Therapeutics press release ( NASDAQ: VYGR ): Q3 GAAP EPS of $0.45 beats by $0.79 . Revenue of $41.1M (+2677.0% Y/Y) beats by $32.07M . Cash, cash equivalents and marketable securities as of September 30, 2022, were $131.6M. Pfizer’s $10M TRACER c...
- Voyager’s TRACER TM capsid platform validated by Pfizer option exercise - - Data characterizing a novel receptor and demonstrating low-dose potential further validate TRACER - - Pipeline programs advancing; development candidate selections for lead p...
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...